--- title: "Caribou Biosciences (CRBU) news: Nasdaq notice" url: "https://aibio.space/companies/caribou-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRBU Nasdaq notice news: Caribou Biosciences regains compliance with Nasdaq $1.00 bid price rule. Caribou Biosciences, Inc. (NASDAQ: CRBU), United States." --- CRBU Caribou Biosciences, Inc. NASDAQ · United States # Caribou Biosciences (CRBU) news CRBU Nasdaq notice news Distress · 2026-10-06 ## [Caribou explores strategic alternatives and ends its allogeneic CAR-T programs](https://aibio.space/news/caribou-explores-strategic-alternatives-ends-allogeneic-car-t-programs/) The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs. ## Latest Caribou Biosciences news 1. 2025-06-23 Listings [Caribou Biosciences regains compliance with Nasdaq $1.00 bid price rule](https://aibio.space/news/caribou-biosciences-regains-compliance-nasdaq-1-00-bid-price-rule/) Caribou's Nasdaq notice covers a window of about two weeks, from June 3 to June 17, 2025, when its closing bid was $1.00 or more. The 8-K does not say what the price did before or after that window. 2. 2025-04-24 Distress [Caribou Biosciences cuts 47 jobs, drops programs, sees cash runway into second half of 2027](https://aibio.space/news/caribou-biosciences-cuts-47-jobs-drops-programs-sees-cash-runway/) Caribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025. ## Caribou Biosciences at a glance - **Ticker**: CRBU - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $112.3 million ### Related companies - [EHOUSE GLOBAL INC](https://aibio.space/companies/ehouse-global/) OTC: EHOS - [Halberd](https://aibio.space/companies/halberd/) OTC: HALB - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) NASDAQ: CCCC - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) NASDAQ: VYGR - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) OTC: MCET - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) NASDAQ: CBIO ### Also on NASDAQ - [Apollomics](https://aibio.space/companies/apollomics/) APLM - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) HRMY - [LEMAITRE VASCULAR INC](https://aibio.space/companies/lemaitre-vascular/) LMAT - [Nexalin Technology](https://aibio.space/companies/nexalin-technology/) NXL - [Aspire-Lakewood Holdings](https://aibio.space/companies/aspire-lakewood/) ASBP - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) CBIO ## Caribou Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$11.2 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | | Research and development | [$109.4 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | [$130.2 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | | Net income (loss) | [-$148.1 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | [-$149.1 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | | Cash from operations | [-$111.0 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | [-$138.2 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | | Cash and equivalents | [$12.4 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/) | [$16.3 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | | Short-term investments | [$127.0 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/) | [$193.2 million](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.2 million, plus short-term investments of $86.1 million, $112.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Underperform Low conviction 2026-10-28 [Caribou Biosciences: Underperform. The price already counts the cash](https://aibio.space/analysis/caribou-biosciences-cash-after-car-t-shutdown/) With both programs shut, the cash that reaches holders is what matters. At $0.4922 the market pays about 7% to 17% more than our estimate of that cash, and the board has not said it will return any. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Caribou Biosciences Has Caribou Biosciences received a Nasdaq deficiency notice? Our latest story on this, dated Jun 23, 2025: "Caribou Biosciences regains compliance with Nasdaq $1.00 bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/caribou-biosciences-regains-compliance-nasdaq-1-00-bid-price-rule/). What is the ticker symbol of Caribou Biosciences? Caribou Biosciences, Inc. trades under the ticker CRBU on NASDAQ. Where is Caribou Biosciences listed? Caribou Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Caribou Biosciences? The SEC Central Index Key (CIK) for Caribou Biosciences, Inc. is 1619856. Its filings are on SEC EDGAR. How many shares does Caribou Biosciences have outstanding? 107,207,513 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Caribou Biosciences listed under? Our directory records Caribou Biosciences, Inc. under United States. What does Caribou Biosciences do? Our directory classifies Caribou Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Caribou Biosciences? The ISIN recorded for Caribou Biosciences, Inc. is US1420381089. Does aibio.space cover Caribou Biosciences? aibio.space lists Caribou Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Caribou Biosciences incorporated? SEC records list its state or country of incorporation as DE. What was Caribou Biosciences's revenue last year? $11.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Caribou Biosciences profitable? Caribou Biosciences, Inc. reported a net loss of $148.1 million for the fiscal year ended Dec 31, 2025, and used $111.0 million of cash in operations, per its annual report to the SEC. How much does Caribou Biosciences spend on research and development? $109.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Caribou Biosciences have? $112.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Caribou Biosciences (CRBU) stock news? Our latest story on Caribou Biosciences, dated Oct 6, 2026: "Caribou explores strategic alternatives and ends its allogeneic CAR-T programs". The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs. [Source](https://aibio.space/news/caribou-explores-strategic-alternatives-ends-allogeneic-car-t-programs/). ## Investor discussion: Caribou Biosciences Members talk about Caribou Biosciences (CRBU). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Caribou Biosciences, newest first. Each line links the filing it comes from. 1. 2026-10-06 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175dex991.htm) 2. 2026-03-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm) 3. 2025-06-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000052/crbu-20250618.htm) 4. 2025-06-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000047/crbu-20250612.htm) 5. 2025-05-08 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1619856/000119312525116051/d86420ds3.htm) 6. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000031/crbu-20250425.htm) 7. 2025-04-24 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424xexx991.htm) 8. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000019/crbu-20250411.htm) 9. 2025-03-10 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000015/crbu-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRBU on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRBU/). ## SEC filings and registration - **SEC name**: Caribou Biosciences, Inc. - **CIK**: 1619856 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CRBU (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710 - **Phone**: 510-982-6030 - **Shares outstanding**: 107,207,513 as of 2026-08-07 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175d8k.htm) filed 2026-10-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000047/crbu-20260617.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/crbu-20260611.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000036/crbu-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/crbu-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000022/crbu-20260423.htm) filed 2026-04-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001619856), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Caribou Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRBU, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Caribou Biosciences, Inc. - **Ticker**: CRBU - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1420381089 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRBU/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/caribou-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Caribou Biosciences (CRBU) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/caribou-biosciences/